Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q3

8129.TEDINET S100Q4UF
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥1.06T2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥1.27T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥950.2bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥8.6bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥5.5bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥13.4bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥18.2bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥9.9bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥14.4bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥10.4bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥9.5bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.9bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥9.6bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥6.9bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥794.4bnat 2022-12-31Cons.Assets
Total assets¥702.4bnat 2022-03-31Cons.Assets
Total assets¥731.5bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥554.0bnat 2022-12-31Cons.Liabilities
Total liabilities¥461.1bnat 2022-03-31Cons.Liabilities
Net assets / equity¥240.4bnat 2022-12-31Cons.Net assets
Net assets / equity¥241.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥238.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥112.9bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥94.3bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥136.092022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥85.92022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥189.72021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥97.982021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥51.582021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥125.12022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥174.482021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥90.072021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio30.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio34.3%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.5%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥43.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥43.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-12-31¥68.8bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-12-31¥68.8bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥4m
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.7bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-12-31¥7.4bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.6bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-12-31¥715m
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-12-31¥1.02T
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-12-31¥983.6bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥36.4bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.8bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥4.9bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥1.2bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥449m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥1.10T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥1.06T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥43.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥9.7bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥43.3bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥43.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.4bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue2021-04-01 → 2021-12-31¥68.9bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2021-04-01 → 2021-12-31¥68.9bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥5m
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2021-04-01 → 2021-12-31¥2.3bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2021-04-01 → 2021-12-31¥6.7bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2021-04-01 → 2021-12-31¥1.4bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥5.3bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2021-04-01 → 2021-12-31¥691m
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue2021-04-01 → 2021-12-31¥913.8bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue external2021-04-01 → 2021-12-31¥876.8bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥37.0bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.6bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥4.2bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥3.1bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥1.0bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥308m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥993.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥950.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥43.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥6.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 418
ItemContextValueUnit
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-43396000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsRetailReportableSegmentsMember1019985000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E02608-000DispensingPharmacyReportableSegmentsMember68843000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember7442000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E02608-000OtherRelatedBusinessReportableSegmentMember4939000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1101210000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-43396000000JPY
Net salesCurrentYTDDuration1057814000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsRetailReportableSegmentsMember6778000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E02608-000DispensingPharmacyReportableSegmentsMember1738000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember715000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E02608-000OtherRelatedBusinessReportableSegmentMember449000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember9681000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-1128000000JPY
Operating incomeCurrentYTDDuration8552000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-02-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第75期第３四半期(自　2022年10月１日　至　2022年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)東邦ホールディングス株式会社
Company name in english cover pageFilingDateInstantTOHO HOLDINGS CO.,LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役ＣＥＯ　　有働　敦
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都世田谷区代沢五丁目２番１号
Telephone number address of registered headquarter cover pageFilingDateInstant０３（３４１９）７８９３
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)管理本部長　兼　財務部長　　水澤　義昭
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都世田谷区代沢五丁目２番１号
Telephone number nearest place of contact cover pageFilingDateInstant０３（３４１９）７８９３
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)管理本部長　兼　財務部長　　水澤　義昭
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE02608
Fund codeFilingDateInstant－
Security codeFilingDateInstant81290
Filer name in japaneseFilingDateInstant
Original text (Japanese)東邦ホールディングス株式会社
Filer name in englishFilingDateInstantTOHO HOLDINGS CO.,LTD.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Current fiscal year start dateFilingDateInstant2022-04-01
Current period end dateFilingDateInstant2022-12-31
Type of current periodFilingDateInstantQ3
Current fiscal year end dateFilingDateInstant2023-03-31
Previous fiscal year start dateFilingDateInstant2021-04-01
Comparative period end dateFilingDateInstant2021-12-31

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass